# A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema

> **NCT06305416** · PHASE3 · RECRUITING · sponsor: **Incepta Pharmaceuticals Ltd** · enrollment: 70 (estimated)

## Conditions studied

- Diabetic Macular Edema
- Diabetic Retinopathy
- Macular Edema
- Macular Degeneration
- Retinal Disease
- Retinal Degeneration

## Interventions

- **DRUG:** Ranibizumab 10mg/ml Injection
- **DRUG:** Lucentis

## Key facts

- **NCT ID:** NCT06305416
- **Lead sponsor:** Incepta Pharmaceuticals Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-30
- **Primary completion:** 2025-10
- **Final completion:** 2025-12
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-06-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06305416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06305416, "A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06305416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*